Notably, it has been shown in migraine patients that CGRP levels after BoNTA treatment are significantly lower in comparison to the CGRP levels obtained before BoNTA treatment [130,131] and, more importantly, that the CGRP decrease is associated to the responsiveness to treatment. Here, CALCA is linked to migraine disorder.